As the number one killer of Americans, heart disease is a scourge that modern medicine is working furiously to contain.

Now, one tiny biotech company, Cardiol Therapeutics (CRDL.Nasdaq), has a promising new CBD-based drug that could have a tremendous impact on heart inflammation.

With a flagship drug that’s sailing through FDA trials, Cardiol Therapeutics and its shareholders could find themselves the beneficiaries of a lucrative Big Pharma takeout.

Dear Fellow Investor,

Heart disease is the number one killer in the U.S. and results, along with stroke, in $269.4 billion in annual health care costs and lost productivity.

The world is in desperate need of drugs that can help address the problem. Those companies who find drugs that can help will likely be rewarded handsomely.

One pharmaceutical company with an excellent chance of providing a solution to heart inflammation is called Cardiol Therapeutics (CRDL.Nasdaq).

Cardiol’s potential breakthrough product is CardiolRx^TM, a pharmaceutical-grade formulation of cannabidiol (“CBD”) that doctors can prescribe to patients with heart trouble.

As you’ll see, initial studies have shown CBD’s effectiveness at reducing heart inflammation and, better yet for investors, CardiolRx^TM has already sailed through Phase I of the FDA’s process for drug approval.

Success with this drug could help millions and set Cardiol Therapeutics up for a lucrative Big Pharma takeout.

But the best news? It’s still trading at a level that could make an eventual takeout a wealth-creating event for early shareholders.

Hope For A Heart Pandemic

Heart disease kills 659,000 Americans every year and is responsible for one out of every four deaths. Almost half the population has some kind of heart disease.

COVID-19 has added to the problem, as the people most likely to get really sick or die from the virus are those with comorbidities associated with diabetes and heart disease.

In addition, the pandemic has created a new group of patients for CardiolRx^TM to treat for myocarditis, an inflammation of the heart that can occur during a severe case of COVID-19.

CBD, the foundation for Cardiol’s new drug, has already been shown to help with cardiac dysfunction. For instance, the Journal of the American College of Cardiology published a pre-clinical study that CBD has a power effect on cardiac dysfunction and scarring of the heart.

This and other pre-clinical trials on CBD strongly suggest that Cardiol’s CBD-based drugs will be effective as well.

Moving Swiftly Through The Approval Process

CardiolRx^TM is initially aimed at treating acute myocarditis, an inflammation of the heart that can have serious consequences, including death.

The drug has already passed through Phase I of the drug approval process.

A double-blind, placebo-controlled study showed the drug is safe and well tolerated, with no serious side-effects reported. And with that study under its belt, CardiolRx^TM has received Investigational New Drug (“IND”) approval from the FDA.

It has since started a multi-national LANCER Phase II/II trial that involves hospitalized COVID-19 patients with a history of, or risk factors for, cardiovascular disease. Trials are already underway in the United States, Mexico and Brazil.

A second Phase II trial is also under way to test CardiolRx^TM’s effectiveness on acute myocarditis.

Success with either of these studies could provide a big boost to Cardiol Therapeutics stock and early shareholders.

A good example is the heart drug company MyoKarida, which skyrocketed 83% after promising early results from its drug Camzyos^TM.

Save

Not A Subscriber Yet?
Get Golden Opportunities For Free

Subscribe to our Golden Opportunities e-letter to receive timely market
updates from the Gold Newsletter research team, plus video
presentations by expert speakers from the New Orleans Conference
— and the Investor’s Guide to Gold and Silver — all at no cost!

CLICK HERE to start your subscription.

Recent Big Pharma Takeouts Provide Template For Cardiol To Follow

Longer term, the model Cardiol Therapeutics is looking to follow is the path carved out by GW Pharmaceuticals and its CBD-based drug called Epidiolex^®.

Epidiolex^® has been found effective at treating epileptic seizures.

If you were an early investor in GW Pharmaceuticals in 2013, you could have owned GW at $8.90 per share when it uplisted from London’s AIM to Nasdaq.

That investment, had you held it through its takeout by Jazz Pharmaceuticals, would have been cashed out at $220 a share — a 2,371.9% return on investment.

MyoKardia provides another example. Bristol Myers Squib paid $225 a share in 2020 to acquire MyoKardia’s heart drug.

Again, early investors in MyoKardia would have realized as much as a 2,150% return on investment in the company.

Such is the money-making power of Big Pharma takeouts…and such is the potential for Cardiol Therapeutics.

Looking For Profits?
Follow The Billionaires

Need one last reason to consider adding Cardiol Therapeutics to your portfolio?

How about this: Some of the world’s richest people have significant stakes in biotech stocks.

The list of those invested in the sector reads like a who’s who of the world’s elite investors. It includes Warren Buffett, Peter Thiel, Bill Gates, Jeff Bezos, and Michael Bloomberg.

Unlike some of the companies this group is invested in, Cardiol Therapeutics is publicly traded, giving you the opportunity to reap gains in the sector just like these billionaires.

With CardiolRx^TM moving quickly through the drug approval process, you’ll want to start doing your research on this company now, before the rest of market catches wind of this story.

CLICK HERE
To Learn More about Cardiol Therapeutics Inc. and Streetlight Confidential